Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
about
Glycaemic control for patients with acute coronary syndromeGlycaemic control for patients with acute coronary syndromeAcarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomesGLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesNew horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute WorkshopCardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.The Akt1 isoform is an essential mediator of ischaemic preconditioningPathological ventricular remodeling: therapies: part 2 of 2.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Role of melatonin in glucose uptake by cardiomyocytes from insulin-resistant Wistar rats.Mitochondrial dysfunction and its impact on diabetic heart.Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose?Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.Epac2-dependent mobilization of intracellular Ca²+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β-cells of phospholipase C-ε knockout mice.Improvement in cardiovascular indices after Roux-en-Y gastric bypass or sleeve gastrectomy for morbid obesity.Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
P2860
Q24197696-6FAB8DBA-728E-48E7-BECD-D7DA1DCFFC84Q26471811-709A189C-B5F5-4B43-ABCB-0B68CCDE06B8Q26778095-E3759095-1523-4360-9F27-D969B7D09B99Q33917887-2EC18F1A-7882-4AEC-8F87-0765391E7198Q35047406-5C5ABC55-5A31-4012-8394-F566E8F5269DQ35821654-91A31E5B-0B96-41D9-80C7-139EDB40FEAFQ35909303-76AB8180-9F16-4CFE-B99D-4DA13FA47CCAQ37007953-30D12B3E-C1BA-4EB2-ACF2-3C56D272FA99Q37023878-B0930CE7-CE0D-42B0-8A92-0E0D34C304FEQ37294231-6F89FDF1-2C1D-4747-B55A-DA5996D440E3Q37312758-1B2CFA69-78C7-4B73-B8B4-5878A3CD9661Q38219490-0CAF8D12-C7FA-401B-9C61-73D6657FA1E9Q38757077-DD48C8AB-79F1-4426-8E29-7E46034523AEQ38946122-8DBF852E-F8E8-49AB-B8FC-5EA41DA10B6DQ41267217-6883AD9E-385B-4387-914B-D3F2A1D13101Q41816192-CEC16D65-0FC2-40FE-9206-7945B623F17AQ41826601-D1A0CE7D-582A-450E-B8C4-7142B24ADF55Q42839735-DE05F340-AF34-43A2-B14F-D266A2B74AC2Q44396877-40359187-756B-4304-ADFD-27DB5A5D1057Q50903830-EB464FD4-D078-47F8-8ABD-7B575E1F8416
P2860
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@en
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@nl
type
label
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@en
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@nl
prefLabel
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@en
Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
@nl
P2093
P356
P1433
P1476
Glucagon-like peptide-1 and myocardial protection: more than glycemic control
@en
P2093
Anjali V Fields
Brandy Patterson
Richard P Shannon
P304
P356
10.1002/CLC.20456
P577
2009-05-01T00:00:00Z